Global HIV Drugs Market 2015-2019

Global HIV drugs market overview

HIV is a type of retrovirus that causes serious complications in humans. It generally spreads via the blood, semen, vaginal fluid, pre-ejaculate, or breast milk. According to the HIV drugs industry forecast, the global market for HIV drugs is envisaged to surpass USD 19,000 million by 2019 owing to the recent rise in HIV patient population. In this market analysis, Technavio’s market research analysts have estimated eminent factors, like the growing HIV patient base, to drive market growth during the forecast period. Lately, it has been observed that the overall patient base for HIV infections is continually increasing. This increase in HIV-related infections will augment the consumption of medications, which in turn will foster the revenues generated by the companies during the forecast period.

Segmentation by class of drugs and analysis of the HIV drugs market

• Multi-class combination products
• Nucleoside reverse transcriptase inhibitors
• Non-nucleoside reverse transcriptase inhibitors
• Protease inhibitors
• Fusion inhibitors
• Entry inhibitors - CCR5 co-receptor antagonist
• HIV integrase strand transfer inhibitors

This market study by Technavio identifies the nucleoside reverse transcriptase inhibitors segment to be the highest revenue-generating segment in this market during the forecast period. This segment is envisaged to surpass USD 5,500 million by 2019 as it consists of drugs that are widely used for the treatment of HIV infections.

Geographical segmentation of the HIV drugs market

• APAC
• EMEA
• Americas

Geographically, the EMEA region is expected to be the highest revenue-generating segment in this market during the forecast period. Factors like the growing patient population and various initiatives taken by the government in this region are responsible for its high revenue generation capacity of more than USD 7,500 million during the forecast period. These factors will aid in HIV drugs market growth.

Competitive landscape and key vendors

This market is highly competitive and contains numerous local and international vendors who increasingly compete with each other to gain prominence in this market. Local vendors in this market are also gaining traction as they have the ability to supply generic versions of the branded drugs to treat HIV-related conditions.

 Key vendors in this market are 

• Bristol-Myers Squibb
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck

Other prominent vendors analyzed in this market study are AbbVie, AstraZeneca, Boehringer Ingelheim, Cipla, Daiichi Sankyo, Emcure, F. Hoffmann-La Roche, Hetero Drugs, Mylan, Pfizer, Shionogi, and Teva Pharmaceutical Industries.

Key questions answered in the report include

What will the market size and the growth rate be in 2019?
What are the key factors driving the global HIV drugs market?
What are the key market trends impacting the growth of the global HIV drugs market?
What are the challenges to market growth?
Who are the key vendors in the global HIV drugs market?
What are the market opportunities and threats faced by the vendors in the global HIV drugs market?
Trending factors influencing the market shares of the EMEA, Americas, and APAC?
What are the key outcomes of the five forces analysis of the global HIV drugs market?

Technavio also offers customization on reports based on specific client requirement.

Related reports

• Global HIV-AIDS Testing Market 2014-2018